Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 8,383 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: serum sample Clear all

Conditions: EGFR Gene Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Laboratory Biomarker Analysis, Nimotuzumab, Nivolumab; Other · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Interventions: docetaxel, cisplatin, 5-FU, IMRT, cetuximab, carboplatin; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma, Non-Hodgkin, Lymphomas: Non-Hodgkin, Lymphomas: Non-Hodgkin Cutaneous Lymphoma, Lymphomas: Non-Hodgkin Diffuse Large B-Cell, Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell, Lymphomas: Non-Hodgkin Mantle Cell, Lymphomas: Non-Hodgkin Marginal Zone, Lymphomas: Non-Hodgkin Peripheral T-Cell, Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia
Interventions: Rituximab, Epratuzumab; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Histiocytosis, Langerhans-Cell
Interventions: Etanercept; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Day to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infection
Interventions: Etanercept (Enbrel); Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Lung Cancer
Interventions: cetuximab, vinflunine; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Burlington, North Carolina • Chapel Hill, North Carolina

Conditions: Colorectal Neoplasms
Interventions: Bevacizumab, Oxaliplatin, Capecitabine, Irinotecan; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Irritable Bowel Syndrome
Interventions: Medical Food, Placebo; Other
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 8 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Metastatic Cancer, Renal Cancer
Interventions: Atezolizumab, Bevacizumab, Entinostat; Drug
Lead sponsor: Roberto Pili; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 4
States / cities: Indianapolis, Indiana • Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Liver Failure
Interventions: Anti-Thymocyte Globulin, ATG (Rabbit), Total lymphoid irradiation; Drug · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Stanford, California

Conditions: Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures
Interventions: denosumab, Placebo, Calcium and Vitamin D; Drug · Dietary Supplement
Lead sponsor: Susan L. Greenspan; Other
Eligibility: 65 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Miscarriage, Recurrent, Abortion, Habitual
Interventions: Gamimune N or Gamunex 10%, normal saline; Biological · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiac Transplantation
Interventions: Daclizumab; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Month to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Macular Edema
Interventions: Ranibizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more

Conditions: Follicular Lymphoma
Interventions: Golcadomide, Rituximab, Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prednisolone, Bendamustine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 31
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 25 more

Conditions: Advanced or Metastatic Solid Malignancies
Interventions: Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab Vedotin-Ejfv, Ipilimumab; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 13
States / cities: Littleton, Colorado • Goshen, Indiana • Boston, Massachusetts + 10 more

Conditions: Cancer of Larynx
Interventions: Cisplatin, Cetuximab, 5-Fluorouracil, Docetaxel; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Inflammation
Interventions: Arm 2: cholecalciferol 50,000 IU, Arm 3: cholecalciferol 100,000 IU, Arm 4: cholecalciferol 200,000 IU, Arm 1: Placebo; Dietary Supplement · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Colorectal Cancer
Interventions: Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg, Placebo for bevacizumab 7.5 mg/kg, Oxaliplatin 85 mg/m^2, Leucovorin 200 mg/m^2, Fluorouracil 400 mg/m^2, Bevacizumab 5 mg/kg, Placebo for bevacizumab 5 mg/kg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,035 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 49
States / cities: Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more

Conditions: Head and Neck Cancer
Interventions: Cetuximab, Nab-paclitaxel, Carboplatin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Nashville, Tennessee • Seattle, Washington

Conditions: Cancer, Solid Tumor
Interventions: IMC-1121B, Moxifloxacin, Diphenhydramine; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 7
States / cities: Atlanta, Georgia • Metairie, Louisiana • Ann Arbor, Michigan + 4 more

Conditions: Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Unresectable Melanoma
Interventions: Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab; Drug · Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Aging
Interventions: Topical anti-aging peptide serum; Drug
Lead sponsor: Frontiers in Bioscience Research Institute and Aging; Other
Eligibility: 50 Years to 100 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Irvine, California

Conditions: Colorectal Cancer
Interventions: RXC004, Nivolumab, Denosumab; Drug · Biological
Lead sponsor: Redx Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Santa Rosa, California • Indianapolis, Indiana • Las Vegas, Nevada + 2 more

Search by objective public record fields.

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL

Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects

Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

SBI in Children With d-IBS

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation

Preventing Osteoporosis Using Denosumab

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients

A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

Effect of a One Time Dose of Cholecalciferol on Serum Concentration of 25-Hydroxyvitamin D and Macrophages

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)